These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 22393246

  • 1. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
    Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF.
    J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
    [Abstract] [Full Text] [Related]

  • 2. Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines.
    Foster KA, Jane EP, Premkumar DR, Morales A, Pollack IF.
    J Neurooncol; 2014 Dec; 120(3):459-72. PubMed ID: 25139025
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
    Jane EP, Premkumar DR, Morales A, Foster KA, Pollack IF.
    J Pharmacol Exp Ther; 2014 Jul; 350(1):22-35. PubMed ID: 24741074
    [Abstract] [Full Text] [Related]

  • 4. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW, van de Kooij B, Verheij M, Borst J.
    Cell Death Dis; 2012 Aug 09; 3(8):e366. PubMed ID: 22875003
    [Abstract] [Full Text] [Related]

  • 5. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE.
    Mol Pharmacol; 2009 May 09; 75(5):1231-9. PubMed ID: 19246337
    [Abstract] [Full Text] [Related]

  • 6. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA.
    Blood; 2008 Oct 01; 112(7):2906-16. PubMed ID: 18591385
    [Abstract] [Full Text] [Related]

  • 7. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
    Yang TM, Barbone D, Fennell DA, Broaddus VC.
    Am J Respir Cell Mol Biol; 2009 Jul 01; 41(1):14-23. PubMed ID: 19097992
    [Abstract] [Full Text] [Related]

  • 8. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, Moreau P, Pellat-Deceunynck C, Amiot M, Le Gouill S.
    Clin Cancer Res; 2011 Sep 15; 17(18):5973-81. PubMed ID: 21821698
    [Abstract] [Full Text] [Related]

  • 9. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K, Huang S, Sinicrope FA.
    Clin Cancer Res; 2008 Dec 15; 14(24):8132-42. PubMed ID: 19088028
    [Abstract] [Full Text] [Related]

  • 10. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
    Spender LC, Inman GJ.
    Mol Cancer Res; 2012 Mar 15; 10(3):347-59. PubMed ID: 22241218
    [Abstract] [Full Text] [Related]

  • 11. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
    Kunami N, Katsuya H, Nogami R, Ishitsuka K, Tamura K.
    Anticancer Res; 2014 Oct 15; 34(10):5287-94. PubMed ID: 25275021
    [Abstract] [Full Text] [Related]

  • 12. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.
    Potter DS, Kelly P, Denneny O, Juvin V, Stephens LR, Dive C, Morrow CJ.
    Neoplasia; 2014 Feb 15; 16(2):147-57. PubMed ID: 24709422
    [Abstract] [Full Text] [Related]

  • 13. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Cancer Res; 2013 Feb 15; 73(4):1340-51. PubMed ID: 23243017
    [Abstract] [Full Text] [Related]

  • 14. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P, Chao BH, Litz J, Krystal GW.
    Mol Cancer Ther; 2009 Apr 15; 8(4):883-92. PubMed ID: 19372561
    [Abstract] [Full Text] [Related]

  • 15. New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
    Pandit B, Gartel AL.
    Prostate; 2010 Jun 01; 70(8):825-33. PubMed ID: 20058240
    [Abstract] [Full Text] [Related]

  • 16. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells.
    Cristofanon S, Fulda S.
    Cell Death Dis; 2012 Nov 29; 3(11):e432. PubMed ID: 23190604
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, Pollack IF.
    Mol Carcinog; 2013 Feb 29; 52(2):118-33. PubMed ID: 22086447
    [Abstract] [Full Text] [Related]

  • 18. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
    Premkumar DR, Jane EP, Pollack IF.
    Cancer Biol Ther; 2015 Feb 29; 16(2):233-43. PubMed ID: 25482928
    [Abstract] [Full Text] [Related]

  • 19. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
    Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF.
    Mol Cancer Ther; 2013 Mar 29; 12(3):326-38. PubMed ID: 23325792
    [Abstract] [Full Text] [Related]

  • 20. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.